← Leaderboards
Radha Rajasingham
University Of Minnesota
$6,079,720
Attributed
$6,079,720
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,079,720 · 3
By mechanism
R01$3,179,431 · 1
U01$1,946,714 · 1
K23$953,575 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota
Same institution · by research overlap
- David R Boulware$24,302,588
- Courtney C Aldrich$9,602,262
- Kirsten Nielsen$10,549,048
- Joel Bazira$1,091,976
- Dirk Schnappinger$17,202,306
Others in their field
Other Emerging Leaders on “Screening”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,487,925
- Lynn Briscoe · Leidos Biomedical Research, Inc.$121,890,535
- Yunda Huang · Fred Hutchinson Cancer Center$58,111,165
- Leonard Freedmand · Leidos Biomedical Research, Inc.$57,401,321
- John Damon Chodera · Sloan-Kettering Inst Can Research$53,758,943
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$33,980,897
Research focus
ScreeningMeningitisRandomized TrialRecommendationCryptococcal MeningitisCryptococcusFluconazolePlasmaInternationalPersonsAfrica South Of The SaharaAntifungal TherapyAntigensAntiretroviral TherapyCessation Of LifeCellsBloodClinical TrialsGuidelinesInfectionMortalityCost-Effectiveness EvaluationCd4 Lymphocyte CountStandard Of Care
Grant awards (15)
An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease$384,686
R01 · FY2025 · AI · contact PI
Enhanced Antifungal Therapy to Improve Survival in Early Disseminated Cryptococcal Infection$356,777
U01 · FY2025 · AI · contact PI
Enhanced Antifungal Therapy to Improve Survival in Early Disseminated Cryptococcal Infection$274,913
U01 · FY2025 · AI · contact PI
An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease$256,919
R01 · FY2025 · AI · contact PI
Enhanced Antifungal Therapy to Improve Survival in Early Disseminated Cryptococcal Infection$638,152
U01 · FY2024 · AI · contact PI
An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease$618,989
R01 · FY2024 · AI · contact PI
Enhanced Antifungal Therapy to Improve Survival in Early Disseminated Cryptococcal Infection$676,872
U01 · FY2023 · AI · contact PI
An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease$630,069
R01 · FY2023 · AI · contact PI
An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease$626,433
R01 · FY2022 · AI · contact PI
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive persons$162,135
K23 · FY2022 · AI · contact PI
An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease$662,335
R01 · FY2021 · AI · contact PI
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive persons$197,860
K23 · FY2021 · AI · contact PI
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive persons$197,860
K23 · FY2020 · AI · contact PI
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive persons$197,860
K23 · FY2019 · AI · contact PI
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive persons$197,860
K23 · FY2018 · AI · contact PI